Acute Kidney Injury

Download as ppt, pdf, or txt
Download as ppt, pdf, or txt
You are on page 1of 42

Acute Kidney Injury

Moises Auron MD, FAAP FACP


Assistant Professor of Medicine and Pediatrics

January 28, 2010


Outline
• Definition
• Etiology and Clinical Presentation
• Diagnosis
• Treatment
Definition
• Acute Kidney Injury Network (AKIN)
– AKI - represent the entire spectrum of acute
renal failure
• RIFLE Classification
– three levels of injury (Risk, Injury, and Failure)
– two outcome measures (Loss and ESRD)

Critical Care. 2007, 11(2):R31


RIFLE Criteria

Limitations:
• Change in creatinine may not
correlate with change in GFR
• Need to know baseline
creatinine.
• No correlation between U/O
and Screat levels
•Should exclude U obstruction

(Acute Dialysis Quality Initiative (ADQI) Group). Critical Care. 2004;8(4):R204-12.


• Abrupt (< 48 h) absolute increase in the
serum creatinine concentration of ≥0.3
mg/dL from baseline
• Increase in the serum creatinine ≥ 50 %
• Oliguria < 0.5 mL/kg per hour for > 6 hrs.

Critical Care. 2007, 11(2):R31


GFR and Creatinine

Dennen P. Crit Care Med 2010; 38(1):261–275


Epidemiology
• Upon admission to hospital – 1%
• During hospitalization – 2-5%
• After Cardiopulmonary bypass. – 5-15%

Thadhani R. NEJM. 1996;334(22):1448-60


Etiology
• Prerenal (40-80% cases)
– Volume depletion
• Blood loss: surgery, trauma, gastrointestinal or
genitourinary bleeding
• Gastrointestinal: vomiting, diarrhea
• Urinary (diuretics, diabetes insipidus)
• Cutaneous losses (burns, fever)
– Decreased Arterial Blood Pressure
• Low Cardiac output
• Cardio renal syndrome type 1
• Sepsis/shock
• Hepatorenal syndrome
• Drugs: ACEI, NSAIDS

Thadhani R. NEJM. 1996; 334:1448–1460


Etiology of low perfusion states

Abuelo JG. NEJM. 2007;357(8):797-805.


Hepatorenal Syndrome

Garcia-Tsao G. HEPATOLOGY 2008;48:2064-2077.


Gines P. N Engl J Med 2009;361(13):1279-90.
AKI in Cirrhosis

Garcia-Tsao G. HEPATOLOGY 2008;48:2064-2077.


Gines P. N Engl J Med 2009;361(13):1279-90.
Cardiorenal Syndrome Type 1

Shamseddin MK. Nat Rev Nephrol. 2009;5:641–649.


Ronco C. European Heart Journal e-pub Dec 25, 2009. doi:10.1093/eurheartj/ehp507
Sepsis and AKI

Schrier RW. NEJM 2004;351(2):159-69.


Etiology
• Renal (5-15%)
– Vascular
• Thrombosis (arterial and venous)
– Cholesterol emboli (post-intervention)
• Renal artery stenosis
• Hemolytic-uremic syndrome
• Malignant hypertension
• Vasculitis (Wegener’s, SLE, PAN, MPA).
• Scleroderma
– Glomerular
• Acute glomerulonephritis: vasculitis, post-infectious (Streptococcus).
– Tubular and interstitial disease
• Acute tubular necrosis (ATN) – ischemia or injury from tubular nephrotoxins
• Nephrotoxic agents: aminoglycosides, amphotericin B, contrast agents
• Rhabdomyolysis
• Tumor lysis syndrome
• Acute interstitial mephritis – Eosinophiluria, drug hypersensitivity
• Nephrolithiasis

Thadhani R. NEJM. 1996; 334:1448–1460


http://path.upmc.edu/cases/case51/dx.html
Ischemic Acute Tubular Necrosis

Abuelo JG. NEJM. 2007;357(8):797-805.


Contrast Induced AKI

Abu Jawdeh BJ. J Hosp Med. 2009;4:500–506.


Solomon R. Radiol Clin N Am. 2009;47:783–788
Rhabdomyolysis

Bosch X. NEJM. 2009;361(1):62-72.


Etiology of AKI in the ICU

Dennen P. Crit Care Med 2010; 38(1):261–275


Acute interstitial nephritis

Needham E. Am Fam Physician 2005;72:1739-46.


AKI and Metabolic Acidosis
• Anion Gap Metabolic Acidosis
– Normal osmolal gap: salicylate and
paraldehyde
– Increased osmolal gap: methanol,
ethanol, isopropyl alcohol and ethylene
glycol
• Ethylene-glycol: calcium oxalate crystals

http://www1.nasa.gov/centers/marshall/news/background/facts/renal.html
Etiology
• Postrenal (10-30%)
– Bilateral urinary tract obstruction
• PUV (children)
• BPH
• Retroperitoneal malignancies
• Urethral strictures
• Nephrolithiasis
• Catheters
• Neurogenic bladder

Thadhani R. NEJM. 1996; 334:1448–1460


British Journal of Radiology.2002;75:177-179
Anderson RJ. Best Pract Res Clinical Anaesth. 2004;18(1):1–20.
Luyckx VA. Nat Clin Pract Nephrol. 2008;4(12): 664-71.
Diagnosis

Anderson RJ. Best Pract Res Clinical Anaesth. 2004;18(1):1–20.


Creatinine and drugs
• Inhibition of secretion of creatinine by the proximal tubule
– Cimetidine
– Trimethoprim
– Pyrimethamine
– Salicylates

• Modification of the production rate and the release of


creatinine:
– Corticosteroids
– Vitamin D metabolites

• Unclear:
– phenacemide

Andreev E. J Int Med 1999; 246: 247-52.


Diagnosis: Urinary Indices

Fe Urea % <35 50 – 65
Fe Uric Acid % <7 >15
Fe Lithium % <7 >20

Esson ML. Ann Intern Med. 2002;137:744-752.


Anderson RJ. Best Pract Res Clinical Anaesth. 2004;18(1):1–20.
Calculation of FENa

                      UNa   x   PCr
FENa (%) =            x    100
                      PNa   x   UCr
Diagnosis: Urinary sediment
x400 x400

Perazella, MA. CJASN ePress. Jan 14 2010 as doi: 10.2215/CJN.06960909


Esson ML. Ann Intern Med. 2002;137:744-752.
Diagnosis: Urinary sediment

Hansel stain

http://missinglink.ucsf.edu/lm/IDS_102_cases_glomerular/Nephritic_syndrome.htm
Kaye M. Kidney International (2008) 73, 980.
Diagnosis – Urinary microscopy

Perazella, MA. CJASN ePress. Jan 14 2010. DOI 10.2215/CJN.06960909


Kanbay M. Int Urol Nephrol. Nov 17 2009. DOI 10.1007/s11255-009-9673-3
Diagnosis: Ultrasound
• R/O obstruction
• Assess renal size and
parenchyma
• Doppler (renal flow and
resistive index)
– Normal < 0.7
– High: intrarenal vascular
disease or arteriosclerosis,
ATN, urinary obstruction
and acute graft rejection.
Ikee R. Am J Kidney Dis 2005 Oct;46(4):603-9.
http://radiology.med.sc.edu/renalultrasound.htm
Diagnosis: CT scan/MRI
• Nephrolithiasis (non-contrast)
• Pyelonephritis
• Renal vein thrombosis
• Assessment of renal arteries
– Avoid gadolinium in GFR < 30 ml/min/1.73m2
Biomarkers of AKI

Soni SS. Blood Purif 2009;28:165–174


Biomarkers of AKI
• Cystatin C - cysteine protease inhibitor
synthesized by all nucleated cells. It is freely
filtered by the glomerulus, reabsorbed
completely by PCT and not secreted.
– Levels of cystatin C are not affected by gender, age,
race or muscle mass.
• IL-18 - proinflammatory cytokine induced in PCT
and is detected in urine following AKI.
– Early predictor of AKI in ARDS (AUC) 0.73.
– More specific for ischemic AKI and its levels are not
deranged in CKD, UTI or nephrotoxic AKI
Soni SS. Blood Purif 2009;28:165–174
Biomarkers of AKI
• Kidney Injury Molecule-1 (KIM-1) - transmembrane
protein markedly overexpressed in PCT in response
to ischemic or toxic AKI.
– Urinary KIM-1 helped to distinguish ischemic AKI from
prerenal azotemia and CKD
• Neutrophil gelatinase-associated lipocalin (NGAL)
- 25-kD protein massively released from renal tubular
cells after injury
– Higher baseline NGAL - increased risk of worsening
residual renal function w/n 1 yr
Ronco C. Critical Care 2007, 11:173.
Bolignano D. Clin J Am Soc Nephrol. 2009;4: 337–344.
Soni SS. Blood Purif 2009;28:165–174.
NGAL as biomarker for AKI

Soni SS. Blood Purif 2009;28:165–174


Prevention of CIN
• Minimize radiocontrast dose
• Isoosmolar radiocontrast media preferred
• I.V. NaHCO3 at 3 mL/kg/hr for 1 hour prior to
radiocontrast exposure, then 1 mL/kg/hr for 6 hours after
• I.V. N-acetylcysteine 1200 mg before procedure, then
1200 mg po bid for total 4 doses.
• If I.V. N-acetylcysteine not available, then P.O. N-
acetylcysteine 600-1200 mg po for 2 doses before and 2
doses after the procedure.
• If already on acute hemodialysis, consider CVVH 6
hours before and for 24 hours after the procedure

Abu Jawdeh BJ. J Hosp Med. 2009;4:500–506.


General management of AKI
• Exclude prerenal causes
• Exclude postrenal causes (US; bladder scan; postvoid residual).
• Review urinary sediment
– muddy brown casts: ATN
– red blood cell casts: glomerulonephritis or vasculitis
– pyuria: acute interstitial nephritis
– Clear sediment or hyaline cast: prerenal or postrenal azotemia
• Evaluate urinary indices
• After confirmation of ATN notify nephrologist when serum creatinine
level is 2.0 mg/dL
• Anticipate dialysis
– oliguric ATN (urine volume < 400 mL/24 hr) - 85% of patients
– nonoliguric ATN (urine volume > 400mL/24 hr) - 30% to 40% of patients.
• Assess for differential diagnoses (ANCA, ANA, ESR, etc.)

Esson ML. Ann Intern Med. 2002;137:744-752.


General management of AKI
• Avoid excessive fluid overload leading to
pulmonary edema.
• Avoid hypotension and maintain euvolemia.
• Treat hyperkalemia.
• Review patient’s medications - necessary dose
adjustments.
• Use enteral alimentation if possible
• Discuss timing for initiation and mode of renal
replacement with nephrologists

Esson ML. Ann Intern Med. 2002;137:744-752.


Vasoactive drugs and AKI
• Norepinephrine - in hypotensive vasodilated
patients with AKI, restoration of BP within
autoregulatory values should occur promptly
with NE.
• Dopamine has no advantages over
norepinephrine.
• Epinephrine and phenylephrine may be similar in
efficacy to noradrenaline – limited data
– Epinephrine: associated with hyperglycemia,
hyperlactatemia, acidosis, and hypokalemia.
• Terlipressin - useful in hepatorenal syndrome

Bellomo R. Crit Care Med 2008; 36(Suppl):S179–S186


Indication for dialysis

Needham E. Am Fam Physician 2005;72:1739-46.


Hepatorenal Syndrome: Treatment

Garcia-Tsao G. HEPATOLOGY 2008;48:2064-2077.


Gines P. N Engl J Med 2009;361(13):1279-90.

You might also like